Format

Send to

Choose Destination
Curr Opin Support Palliat Care. 2007 Oct;1(3):187-91. doi: 10.1097/SPC.0b013e3282efd689.

Management of hormone refractory prostate cancer.

Author information

1
UCSF Comprehensive Cancer Center, University of California, San Francisco, California 94115, USA. amlin@medicine.ucsf.edu

Abstract

PURPOSE OF REVIEW:

This review highlights the most interesting developments and outstanding issues surrounding the management of hormone-refractory prostate cancer published in the medical literature during the past year.

RECENT FINDINGS:

Recent research has reported poor health-related quality-of-life outcomes for patient with hormone-refractory prostate cancer treated in standard clinical practices. In addition, age-related differences in survival appear to exist for patients with hormone-refractory prostate cancer. Two potential future therapies for hormone-refractory prostate cancer, sipuleucel-T and the combination regimen of docetaxel and DN-101, demonstrate promising preliminary clinical data in terms of improving survival while minimizing toxicity. A variety of novel agents has been tested for hormone-refractory prostate cancer, including pertuzumab and BMS-275291, which may stabilize disease with minimal toxicity. In terms of bone-related health, skeletal-related events have been found to be associated with worse survival and health-related quality of life outcomes.

SUMMARY:

Data reported during the past year have implications for future research directions. This direction includes the need for continued exploration of health-related quality of life and age-related outcomes, further study of the disease-stabilizing effects of novel therapies and their translation into improved survival, as well as directed efforts to continue preventing skeletal-related events, which may impact survival and health-related quality of life.

PMID:
18685361
DOI:
10.1097/SPC.0b013e3282efd689
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center